US Patent

US8927540 — Pyridazinone derivatives

Method of Use · Assigned to Merck Patent GmbH · Expires 2028-07-21 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pyridazinone derivatives that inhibit tyrosine kinases, particularly Met kinase, for use in treating tumors.

USPTO Abstract

Compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 4â² , have the meanings indicated in Claim 1 , are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3078`	—	tepotinib-hydrochloride

Patent Metadata

Patent number: US8927540
Jurisdiction: US
Classification: Method of Use
Expires: 2028-07-21
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.